Vicebio Closes $100M in Series B Financing
Vicebio Ltd, a UK-based biopharma company, has secured $100 million in Series B funding, led by new investor TCGX, with participation from Goldman Sachs, Avoro Ventures, and venBio.
This financing round will accelerate the development of next-generation vaccines targeting respiratory viruses like RSV and hMPV using Vicebio’s innovative Molecular Clamp technology.
The company recently initiated a Phase I clinical trial for its bivalent vaccine, VXB-241, which targets RSV and hMPV, both major causes of respiratory illness, especially in vulnerable populations.
Dr Emmanuel Hanon, Chief Executive Officer of Vicebio, said in a press release:
"The support from these high-calibre investors underscores the robust data package we have generated for VXB-241, highlighting the significant potential of our proprietary Molecular Clamp technology to develop next-generation vaccines against respiratory viruses."
For Vicebio, this new funding will also support the advancement of Vicebio’s broader pipeline, including a trivalent vaccine that addresses additional viruses such as Parainfluenza.
Vicebio's Molecular Clamp technology, initially developed at The University of Queensland, stabilizes viral proteins, creating highly effective vaccines.
- Vicebio aims to make these vaccines easy to produce and administer, offering them in prefilled syringes for convenient use.
With strong backing from experienced investors in the industry and promising early results, Vicebio is well-positioned to address significant unmet medical needs in respiratory virus prevention.
Initial data from the ongoing trial is expected by mid-2025.
